Company to Participate in BIO Partnering Summit and Present Phase 1 Ketamir-2 Data at American Association for Cancer ...

Life-saving antibiotics that could treat severe infections in babies and children aren't accessible due to a lack of data ...

Novo Nordisk NVO announced positive top-line data from a late-stage study in its global REIMAGINE clinical study program for ...

Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...

Rocatinlimab, targeting the OX40 pathway, shows significant efficacy in moderate to severe atopic dermatitis, marking a new therapeutic class in disease management. Long-term melanoma data reveal ...

PF'3944 is an ultra-long-acting fully biased GLP-1 receptor agonist (RA). It is being developed as a single agent weekly and as a monthly therapy, and in combination with various peptides including an ...

Licensed scientific and clinical intelligence integrated into the 3RnD platform to support AI-Driven Discovery and ...

Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to ...

The authors thank the patients who volunteered to participate in the study, their families and caregivers, the physicians and nurses who cared for the patients and supported this clinical trial, staff ...

PONTE VEDRA, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the ...

In a new publication, researchers from the German Center for Diabetes Research (DZD) and the University of Medicine ...